Article ID Journal Published Year Pages File Type
2802777 Growth Hormone & IGF Research 2011 7 Pages PDF
Abstract

ObjectiveThe objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment.DesignNormative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n = 4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database).ResultsThe overall mean QoL-AGHDA score of the general population was 4.8 ± 5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p = 0.20), whereas age was a significant predictor (p < 0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9 ± 6.5 (p < 0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment.ConclusionsThis study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology
Authors
, , , , , , , , ,